Blazar SAS is a startup based at Station F and incorporated in France, in the context of the accelerator Entrepreneur First. The focus of Blazar is to define and detect signatures of response to cancer therapies.

Immunotherapies are treating durably cancer patients that a few years ago would have had little therapeutic options; cancer patients have a huge variability of responses to immunotherapy, thus the prediction of response is crucial to achieving durable treatments. Blazar is building a software platform to predict which patients will have benefit from specific cancer therapies, using machine learning methods on clinical data.

Integrating clinical datasets (imagery, genetic, genomic, outcome and others) we identify patterns of response. Our solution will impact clinical trial design, patient stratification and clinical decisions.

Further information can be found on Youtube.

The founders are Dora Sabino and Renan Pereira. Dora worked in cancer research in academic and industry settings (PhD, Cambridge UK) and Renan is a data scientist/ machine learning engineer (MsEng E.C. Marseille) with big corp and startup experience. Both are fully dedicated to Blazar and focus on patient benefit deep tech solutions. The founding team initiated their work in November 2018 and incorporated in February 2019, having received pre-seed investment from Entrepreneur First and Plug and Play Silicon Valley.